COVID-19 outcomes in patients with Dermatomyositis: A registry-based cohort analysis.

ABSTRACT:

Background

Patients with rheumatic diseases (RDs) like DM are known to be vulnerable towards various types of infections due to aggressive disease activity mandating high dose immunosuppressive therapy. The severity of COVID-19 in RDs is limited in literature due to the heterogeneous nature of the condition. Therefore, specific details on mortality is essential to navigate any precautions required in the treatment.

Objectives

To determine outcomes of COVID-19 in DM as compared to controls, and identify the risk association of gender, race, interstitial lung disease, neoplasms, and use of immunosuppressant.

Methods

Retrospective data of individuals with DM and COVID-19 and the general population with COVID-19 between January 2020 to August 2021 was retrieved from the T

SUBMITTER: Pakhchanian H 

PROVIDER: S-EPMC9142211 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature